Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05226143 · ClinicalTrials.gov registry record · NA
A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area
A NA study of Dermatitis, Atopic, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
- Completed
- Registry status
- NA
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT05226143 is a NA study of Dermatitis, Atopic that has completed, run by Johnson & Johnson Consumer Inc. (J&JCI). The registered enrollment target is 37 participants, below the 396-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05226143, a NA study of Dermatitis, Atopic, has completed, sponsored by Johnson & Johnson Consumer Inc. (J&JCI).
- COMPLETED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the efficacy (assessed by clinical evaluation of eczema/atopic lesion severity \[atopic dermatitis severity index {ADSI} scoring\] and perceived benefits in itch \[visual analog score {VAS} scoring\]) and tolerability (assessed by clinical grading) of an investigational spot treatment Gel Cream when used on a target site of participants with mild to moderate atopic dermatitis.
Conditions Studied
Interventions
- OTHER Gel Cream
Study Locations (1)
North Carolina
- Dermatology Consulting Services, PLLC - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2022-02-21 |
| Est. Completion | 2022-03-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05226143
The ClinicalTrials.gov registry entry for NCT05226143 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 396-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (91% lower). The listed sponsor is Johnson & Johnson Consumer Inc. (J&JCI), which has 40 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 1 intervention - of which Gel Cream is the first listed.
NCT05226143 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05226143 about?
NCT05226143 is a clinical study titled "A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area". The purpose of this study is to evaluate the efficacy (assessed by clinical evaluation of eczema/atopic lesion severity \[atopic dermatitis severity index {ADSI} scoring\] and perceived benefits in itch \[visual analog score {VAS} scoring\]) and tolerability (assessed by clinical grading) of an inve...
What is the current status of trial NCT05226143?
This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2022-02-21. Estimated completion is 2022-03-09.
What conditions does trial NCT05226143 study?
This clinical trial studies the following conditions: Dermatitis, Atopic.
What interventions are being tested in trial NCT05226143?
The interventions under investigation include: Gel Cream (OTHER).
Who is sponsoring clinical trial NCT05226143?
This trial is sponsored by Johnson & Johnson Consumer Inc. (J&JCI), which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05226143 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
Improving Therapeutic Patient Education for Atopic Dermatitis: Evaluation of a Parent Handbook
COMPLETED · NA
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
RECRUITING
-
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.